PVA TePla's Growth Ambitions Tested by Earnings Dip Amid Joint Lab Push
Published on 07/20/2026 at 17:06 | Redaktion boerse-global.de
The disconnect between operational momentum and market perception has rarely been starker at PVA TePla. While the specialist for crystal growing and vacuum technology has just posted a staggering 164% surge in order intake for the first quarter, its bottom line has swung into the red — leaving investors to weigh record demand against a deliberate, and costly, investment push.
Order intake jumped to €121.6 million in the opening three months of 2026, sending the book-to-bill ratio to 1.9 and signaling a sharp acceleration in new business. Yet the same period saw earnings before interest and tax (EBIT) slide to minus €1.3 million, compared with a profit of €5.9 million a year earlier. PVA TePla attributed the shortfall to planned upfront spending on personnel, infrastructure and sales — moves designed to secure capacity for the growth that those record orders imply.
The market has responded with caution. The stock, which changed hands at €36.98 in recent trading, has shed around 15% over the past month, retreating from the 52-week high of €46.70 touched in early July. Even so, the shares still trade more than 90% above the February trough of €19.32, and the year-to-date gain remains north of 60% — a reflection of how far the rally had run before the consolidation set in.
Should investors sell immediately? Or is it worth buying Pva Tepla?
Against that backdrop, the company has continued to lay groundwork for the future. Early in July, PVA TePla announced the creation of a joint laboratory with the Fraunhofer Institute for Integrated Systems and Device Technology (Fraunhofer IISB) in Erlangen. The "Joint Lab" is tasked with developing and producing small industrial batches of aluminium nitride (AlN) substrates, a material prized for its thermal resilience and electrical insulation properties in high-power electronics. The partnership marries PVA TePla’s process expertise in crystal growth with Fraunhofer’s research infrastructure, and aligns with the company’s strategic push into the semiconductor industry’s next-generation materials.
Management’s conviction in the strategy has been backed by personal capital. Chief executive Jalin Ketter bought shares worth €21,095 in November 2025, while supervisory board member Dr. Myriam Jahn picked up stock worth €21,800 in December last year at an average price of €21.80 — a level that now sits comfortably in the money.
At the annual general meeting in Giessen in mid-June, Ketter reaffirmed the company’s growth trajectory and pointed to the sharp upturn in order intake as evidence of an operational turnaround. The full-year guidance remains unchanged: revenue of between €255 million and €275 million, with EBITDA in a range of €26 million to €31 million. The next real test of that forecast comes on August 6, when PVA TePla is due to publish its first-half and second-quarter results — the first opportunity for the market to see whether the investment phase is starting to translate into profit.
Ad
Pva Tepla Stock: New Analysis - 20 July
Fresh Pva Tepla information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
